Evaluation of Perioperative Celecoxib for Hip Arthroscopy

NCT02779166 | Completed Results

• 1 other identifier: STU00067550
• Study Type: interventional
• Target: 98
• Locations: 0 countries
• Sites: N/A

Brief Summary

Celecoxib is commonly used for perioperative pain control for certain orthopaedic procedures. It has been shown to be successful in assisting in pain control for knee arthroscopy. It has not previously been studied in hip arthroscopy. This is a double blinded randomized controlled trial to determine the efficacy of celecoxib in perioperative pain control for hip arthroscopy.

Conditions

Hip Labral Tears

Keywords

hip arthroscopy

Outcome Measures

Primary Outcomes (3)

• Visual Analog Score for Pain (VAS) in the Immediate Post Operative Period

  The pain VAS is a uni dimensional measure of pain intensity. It is a continuous scale comprised of a 0-10 pain rating. A score of 0 indicates no pain while a score of 10 would indicate extreme pain.

  Pre operative on day of surgery, immediately following OR close, 1 hr post operatively, 2 hrs post operatively

• Total Narcotic Consumption in the Post Anesthesia Care Unit (PACU)

  Monitored consumption of narcotic medications following surgery, measured in morphine equivalents

  duration of PACU stay,immediate post op period up to a maximum of 4 hours postoperatively

• Time to Discharge Following Surgery

  Total time to discharge from OR close following surgery, measured in minutes

  time from OR to discharge, up to a maximum of 6 hours postoperatively

Study Arms (2)

Intervention

EXPERIMENTAL

Received 400mg celecoxib prior to surgery

Drug: Celecoxib

Placebo

PLACEBO COMPARATOR

Received placebo pill prior to surgery

Drug: placebo

Interventions

Celecoxib DRUG

Received 400mg celecoxib prior to surgery

Intervention

placebo DRUG

Placebo

Eligibility Criteria

• Age: 18 Years - 89 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients who are undergoing a hip arthroscopy procedure at Northwestern Memorial Hospital with Dr. Michael Terry.

You may not qualify if:

• Pregnant women and any patient under the age of 18 years.

Sponsors & Collaborators

• Northwestern University: lead

MeSH Terms

Interventions

Celecoxib

Intervention Hierarchy (Ancestors)

Benzenesulfonamides; Sulfonamides; Amides; Organic Chemicals; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Sulfones; Sulfur Compounds; Pyrazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: Dr. Michael Terry
• Organization: Northwestern Univeristy Department of Orthopaedic Surgery

312-926-4444

Study Officials

• Michael Terry, MD

  Northwestern University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: May 13, 2016
• First Posted: May 20, 2016
• Study Start: August 1, 2012
• Primary Completion: January 1, 2016
• Study Completion: May 1, 2016
• Last Updated: September 23, 2019
• Results First Posted: May 14, 2019

Record last verified: 2019-09